Circulating CD147 predicts mortality in advanced hepatocellular carcinoma
Aimei Lee, Anthony Rode, Amanda Nicoll, Annette E Maczurek, Lucy Lim, Seok Lim, Peter Angus, Ian Kronborg, Niranjan Arachchi, Alexandra Gorelik, Danny Liew, Fiona J Warner, Geoffrey W McCaughan, Susan V McLennan, Nicholas A Shackel
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | WILEY-BLACKWELL | Published : 2016
BACKGROUND AND AIM: The glycoprotein CD147 has a role in tumor progression, is readily detectable in the circulation, and is abundantly expressed in hepatocellular carcinoma (HCC). Advanced HCC patients are a heterogeneous group with some individuals having dismal survival. The aim of this study was to examine circulating soluble CD147 levels as a prognostic marker in HCC patients. METHODS: CD147 was measured in 277 patients (110 HCC, 115 chronic liver disease, and 52 non-liver disease). Clinical data included etiology, tumor progression, Barcelona Clinic Liver Cancer (BCLC) stage, and treatment response. Patients with HCC were stratified into two groups based upon the 75th percentile of CD1..View full abstract
Awarded by Australian Government National Health and Medical Research Council
This study was funded by the Australian Government National Health and Medical Research Council Grant ID 512283.